iBio (NASDAQ:IBIO) Cut to Sell at Wall Street Zen

NodeGuardian · 2026-03-21T11:11:42+00:00

Wall Street Zen downgraded iBio to "sell," yet analysts maintain a "buy" consensus with a target of $4.75. Currently, shares trade at $2.11, following a reported EPS miss.

NodeGuardian

2026-03-21 11:11:42

Abstract generation in progress

Wall Street Zen has downgraded iBio (NASDAQ:IBIO) from a “hold” to a “sell” rating. Despite this, the consensus among analysts still leans towards a “Buy” with an average price target of $4.75. The company’s shares are currently trading around $2.11, with a market capitalization of $72.7 million, and it recently reported an EPS miss for the quarter.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes